1/22
Looks like no tags are added yet.
microtubule agents
Vincristine (natura; products)
• Destabilizes microtubules & disrupts mitosis
• ALL, NHL, HD (as ‘Oncovin’ in BEACOPP & MOPP); others...
• Adverse events
– Bone marrow suppression, alopecia
– Neurotoxicity, constipation
• Neurotox. distinct from cisplatin (No
nephrotoxicity)
– SIADH: Syndrome of Inappropriate Antidiuretic
Hormone (aka vasopressin)
• Fluid retention hyponatremia
– Headache, N/V, convulsions, coma
– Vesicant: use central line for admin
– Fatal if given intrathecally
vesicant drug extravasations
vincristine extravasation
Doxorubicin extravasation
microtubule agents Paclitaxel (taxol) (natural products)
• Stabilizes microtubules, blocks mitosis
• Breast and ovarian cancers
• Very promising results when given
i.p. rather than i.v. for ovarian cancer
• DLTs = peripheral neuropathy, myelosuppresion
• Also hypersensitivity
– Urticaria & bronchospasm
– From formulation (cremaphor)
topoisomerase inhibitors (natural products)
Type I Topoisomerases nick & reseal 1 strand of DNA
Type II Topoisomerases cut & rejoin 2 strands of DNA
irinotecan (topoisomerase inhibitors- natural products)
Rationale:
• Inhibits TopoI —> ssDNA breaks
• TopoI is over-expressed in some tumors
Tox/ADRs:
• Profuse diarrhea (“I ran to the can...”) = Myelosuppression
• Nausea/vomiting (oral); ~alopecia; metallic taste (when given i.v.)
etoposide (topoisomerase inhibitors- natural products)
Rationale/MOA:
- Inhibits Topo II —> irreparable dsDNA breaks
Tox/ADRs:
• DLT (dose-limiting toxicity) = myelosuppression
• Nausea/vomiting (oral); ~alopecia; metallic taste (when given i.v.)
doxorubicin (aka adriamycin or hydroxydaunorubicin) 3-fold mech
1. Binds/intercalates into DNA
2. Generates free radicals
damage to DNA & lipids
3. Causes DNA strand breaks via inhibition of Topo II
tamoxifen
inhibits estrogen-dependent functions
anti-estrogens & anti-androgens (hormonal agents)
• In cancers arising from endocrine-regulated tissues, the
tumor cells often retain a trophic response to and/or
dependence on specific hormones
• Thus, blocking specific hormone function (e.g. via a
hormone receptor antagonist) can exert anti-tumor effect
how estrogen works on breast & breast cancer cells
estrogen enters the cell and binds to an estrogen receptor
the receptor binds to DNA which triggers cell proliferation
tamoxifen (an anti-estrogen)
*Same theory can be used for testosterone-dependent
tumors (e.g. anti-androgens for prostatic carcinoma)
uses:
ER+ breast cancers
tox/ADRs:
Very different MOA Very different ADRs
Common: Hot flashes, menstrual changes, low LDL,
vaginal discharge & uterine bleeding
Occasional: nausea (delayed), hypercalcemia, blood
clots, cataracts, ‘chemo brain’
specials:
Competitive ER ‘antagonist’, but…
Acts as partial agonist in some tissues (endometrium,
bone, liver); thus, technically a ‘SERM’ (selective
estrogen response modifier), unlike other true
antagonists (e.g. fulvestrant)
—> increased incidence of secondary endometrial cancer
STI571/Imatinib/Gleevec (kinase inhibitor)
world’s first treatment for a cancer based on its specific, genetic cause
however…
Despite its rational design, imatinib shows significant cross-
reactivity/inhibition with other proteins (c-Kit, PDGFR – both tyrosine kinases)
Good News: Shows promise for use in tumors is which these proteins are
causally dysregulated
Bad News: The human animal is more complex than even the most rational of designs (so far)
increasing emergence of primary & acquired resistance to imatinib
imatinib (a kinase inhibitor)
uses:
Ph+ CML & ALL; c-kit+ GIST (gastrointestinal stromal tumors)
ADME:
Complex interactions with CYP450s as both a
substrate and an inhibitor ( high potential for drug-
drug interactions)
tox/ADRs:
DLT = myelosuppression
edema (ankle, periorbital); N/V
specials:
First genotype-specific chemotherapeutic;
Cross-reactive with c-kit & PDGFR
Increasing emergence of 1o & 2o resistance
2nd & 3rd gen BCR-Abl inhibitors developed based on
molecular analysis of resistance-conferring mutations
CTLA4
—> ipilimumab
PD-1/PD-L1
—> pembrolizumab
(-) factors on T-cell when trying to kill tumor cell
PD-1
CTLA4
(+) factor on T-cell when trying to kill tumor cell
TCR
pembrolizumab (immune checkpoint inhibitors)
uses:
NSCLC (1st); melanoma,
bladder, HD, RCC, HCC,
HNSCC, cervical CA, …
rationale:
These cancers express
PD-L1 that shields them
from immune/T-cell
recognition. Blocking PD-
1 prevents this blockade.
tox/ADRs:
quite well-tolerated
Common: fatigue, myalgia,
itch, some GI distress
Serious/rare: Pneumonitis;
colitis; hepatitis
antimetabolites
methotrexate
5-fluorouracil
6-mercaptopurine
alkylating/DNA-damaging agents
cyclophosphamide
cisplatin
doxorubicin
topoisomerase inhibitors
doxorubicin
irinotecan
etoposide
microtubule poisons
vincristine
Taxol
targeted therapies
tamoxifen
imatinib/Gleevec
pembrolizumab